Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.

Assays focus on accelerating cancer research.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Collaboration leverages two CDx assays from Thermo Fisher to support greater access to genomic testing for cancer patients in Japan and the United States.

Joint development collaboration to bring leading-edge nanopore sequencing into clinical laboratories at Mayo Clinic to increase understanding and improve treatment of cancer and genetic disorders.

Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models.